ReviewTherapeutic advances in medical oncology2017
Current understanding and approach to well differentiated lung neuroendocrine tumors: an update on classification and management.
Review in Therapeutic advances in medical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Two types of ectopic Cushing syndrome or a continuum? Review.Pituitary · 2018Pooled it
- Morphology first: preserving diagnostic hierarchies in high-grade neuroendocrine neoplasms across organ sites.Endocrine · 2026Article
- The Role of Plant-Derived Natural Products as a Regulator of the Tyrosine Kinase Pathway in the Management of Lung Cancer.Current issues in molecular biology · 2025Review
- Article
- Relation between WHO Classification and Location- and Functionality-Based Classifications of Neuroendocrine Neoplasms of the Digestive Tract.Neuroendocrinology · 2024Review
- Prognostic factors for pulmonary carcinoid with positive lymph node after surgical resection: a SEER database study.General thoracic and cardiovascular surgery · 2023Article
- Added prognostic value of molecular imaging parameters over proliferation index in typical lung carcinoid: an [18F]FDG PET/CT and SSTR imaging study.Annals of nuclear medicine · 2023Article
- A multidisciplinary approach to the work up and management of pulmonary carcinoid tumors and DIPNECH: a narrative review.Translational lung cancer research · 2022Review
- Long-term survival analysis of sublobar resection versus lobectomy for older patients with early-stage pulmonary carcinoid tumour: a database-based propensity score-matched study.Aging clinical and experimental research · 2022Article
- Article
- Bronchial carcinoid tumor managed with bronchial artery embolization before endobronchial resection: A case report.Thoracic cancer · 2021Article
- A miR-375/YAP axis regulates neuroendocrine differentiation and tumorigenesis in lung carcinoid cells.Scientific reports · 2021Article
- Article
- IGF1R and MAPK15 Emerge as Potential Targets of Pentabromobenzylisothioureas in Lung Neuroendocrine Neoplasms.Pharmaceuticals (Basel, Switzerland) · 2020Article
- High Expression of NEK2 and PIM1, but Not PIM3, Is Linked to an Aggressive Phenotype of Bronchopulmonary Neuroendocrine Neoplasms.Endocrine pathology · 2020Article
- Diagnostic imaging of typical lung carcinoids: relationship between MDCT,La Radiologia medica · 2020Article
- Diagnostic and Management Pathways for Pulmonary Carcinoid Tumours in the United Kingdom: Results from the National Lung Neuroendocrine Tumour Pathway Project.International journal of endocrinology · 2020Article
- Metastatic small cell neuroendocrine carcinoma of the submandibular gland from the lung: A case report.Medicine · 2020Article
- [Surgical Resection and Prognosis of Bronchopulmonary Carcinoid].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2019Article
- Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study.The oncologist · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroendocrine tumors (NETs) are rare neoplasms that can arise from any tissue. They are classified based on embryonic gut derivative (i.e. foregut, midgut and hindgut) with midgut tumors being the most common (e.g. gastrointestinal NET). The second most common category of NETs is that which arises from the lung. In fact, 25% of primary lung cancers are NETs, including small cell lung cancer (SCLC), which comprises 20% of all lung cancers. The remaining 5% are large cell neuroendocrine cancer (LCNEC, 3%), typical carcinoids (TCs, 1.8%), and atypical carcinoids (ACs, 0.2%). The less common TCs/ACs are well differentiated lung NETs. Their incidence has been increasing in more recent years and although these tumors are slow growing, advanced disease is associated with poor survival. There have been advances in classification of lung NETs that have allowed for more appropriate management upfront. They are cured by surgical resection when disease is limited. However, advanced and metastatic disease requires medical therapy that is ever changing and expanding. In this review, the aim is to summarize the current understanding and classification of well differentiated lung NETs (i.e. TCs and ACs), and focus on recent updates in medical management of advanced disease, along with a brief discussion on potential future discoveries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.